A number of chain cancellations have intensified competition in the pharmacy market
Time of Update: 2022-05-11
[Pharmaceutical Network Market Analysis] Recently, the Hubei Provincial Food and Drug Administration issued an announcement stating that according to relevant regulations, the enterprise decided to cancel the "Drug Business License" of Hubei Yifeng Alkang Pharmacy Chain Co.
Innovent and Reindeer Medical's BCMA CAR-T was granted "orphan drug" designation by the US FDA
Time of Update: 2022-05-03
In February 2021, IBI326's therapy for R/R MM has been included in the "Breakthrough Therapy Drug" category by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) .
Baiyunshan's cash flow has increased by 9 times, and the joint mining price of the eight provinces has been cut by more than 90
Time of Update: 2022-04-16
(National Medical Insurance Administration) Market tide Unnamed medicine faces the risk of termination of listing On March 21, the Shenzhen Stock Exchange issued a letter of concern about Shandong Weiming Biology.
Dupixent in the treatment of infantile eczema patients reaches the phase 3 clinical endpoint
Time of Update: 2021-10-23
The data shows that at the 16th week, compared with the standard treatment, the topical corticosteroid (TCS) was added to the topical corticosteroid (TCS), which significantly reduced the patient's overall disease severity and significantly improved the patient's skin Symptom clearance, itching, and health-related quality of life indicators .
Hausen's Class 1 new drug "Peihuaxi hippocampus" declares for listing
Time of Update: 2021-10-10
Article source: Medical Rubik's Cube InfoAuthor: Shi BeiOn September 30, the official website of CDE showed that the listing application for Peihuaxi hippocampal peptide injection, a new class 1 drug of Hausen Pharmaceuticals, was accepted by the State Food and Drug Administration .
Many places are continuing to strengthen the supervision of medical device products, and machinery companies will face major challenges
Time of Update: 2021-10-10
In addition, the Anhui Provincial Food and Drug Administration has also continued to promote the quality and safety supervision of medical devices for epidemic prevention and control in the province in the near future, and organized supervisors to carry out centralized unannounced inspections of 11 medical device manufacturers .
Announcement of the Market Supervision Administration of Inner Mongolia Autonomous Region on the Sampling Inspection of 663 Batches of Food (No. 40 of 2021
Time of Update: 2021-08-02
The problem of excessive use of food additives (1) The vermicelli (medium width) produced and sold in Room 26, Lufeng Food Processing Park, Jining District (production date 2020/11/27), the residual amount of aluminum (dry sample, calculated as Al) does not meet food safety National standard regulations .
The second domestic third-generation EGFR-TKI was approved for listing
Time of Update: 2021-03-19
At the same time, the drug is targeted at EGFR exon 19 deletion or extracellular The Phase III clinical trial for the treatment (first-line treatment) of adult patients with locally advanced or metastatic non-small cell lung cancer with a substitution mutation of Exon 21 (L858R) was launched in June 2019, and it is expected to submit a marketing application in 2022.
Hesco Class 1 new drugs are about to be approved for a $10 billion market for narcotic drugs
Time of Update: 2021-03-02
According to the Hesco announcement, HSK3486 emulsion is the company developed a new intravenous anesthetic drug with independent intellectual property rights, intended for surgical whole hemp induction, endoscopy sedatives / anesthesia, ICU sedation and other indications, drug registration classified as chemical drugs 1 category.
FDA approves use of Vascepa-assisted therapy to reduce the risk of cardiovascular disease
Time of Update: 2021-02-22
about the Vascepa Vascepa is the first FDA-approved complementary therapy to be used as a maximum to-dosage statin to reduce triglyceride levels and increase the risk of cardiovascular disease in patients.
Vascepa has been approved by the FDA to reduce triglyceride levels in patients with severe high triglycerides.
Baotai was approved by the NMPA to issue a bat1006 injection clinical trial notice
Time of Update: 2021-01-09
BAT1006 injection is a monoantigen developed by Biopharmaceutical Co., Ltd., and its active ingredient is an antibody of target human skin growth factor-2 (HER2) expressed by Chinese hamster ovarian cells, which belongs to immunoglobulin IgG1.
Bi Jingquan is the executive vice president of the National Economic Center
Time of Update: 2020-12-30
, a member of the Economic Committee of the 13th National Committee of the Chinese People's Political Consultative Conference (CPPCC) and a former deputy director of the Development Research Center of the State Council, ceased to serve as deputy director of the National Research Center earlier this year.
Global pharmacopeia comparison of pharmaceutical water
Time of Update: 2020-10-04
The 2020 edition of the Chinese Pharmacopoeia has been published, although the Pharmacopoeia contains 0261 pharmaceutical water general rules, but in the water production process, process control, ope
Rare pediatric epilepsy new drug! Fintepla (Finteplamin) Treatment of Dravet Syndrome Phase 3 Phase III Clinical: Significant reduction in convulsive seizures
Time of Update: 2020-09-26
results showed that the study achieved the main goal: patients in the Fintepla 0.7mg/kg/day group had an average monthly reduction in convulsive seizures by 64.8% compared to the placebo group.
ViaBio and Langhua Pharmaceutical Strategic Integration Agreement accelerate the upgrading of the innovative pharmaceutical industry service chain
Time of Update: 2020-08-12
viaBio will further strengthen and expand the drug research, development and production capacity of both parties, including but not limited to expanding their CMC capabilities and integrating their business operations with the Group's existing operations, based on the existing core strengths.